These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212 [TBL] [Abstract][Full Text] [Related]
24. Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF Antonello ZA; Hsu N; Bhasin M; Roti G; Joshi M; Van Hummelen P; Ye E; Lo AS; Karumanchi SA; Bryke CR; Nucera C Oncotarget; 2017 Oct; 8(49):84743-84760. PubMed ID: 29156680 [TBL] [Abstract][Full Text] [Related]
25. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in Ribas A; Daud A; Pavlick AC; Gonzalez R; Lewis KD; Hamid O; Gajewski TF; Puzanov I; Wongchenko M; Rooney I; Hsu JJ; Yan Y; Park E; McArthur GA Clin Cancer Res; 2020 Jan; 26(1):46-53. PubMed ID: 31732523 [TBL] [Abstract][Full Text] [Related]
26. Vemurafenib in non-small-cell lung cancer patients with BRAF Mazieres J; Cropet C; Montané L; Barlesi F; Souquet PJ; Quantin X; Dubos-Arvis C; Otto J; Favier L; Avrillon V; Cadranel J; Moro-Sibilot D; Monnet I; Westeel V; Le Treut J; Brain E; Trédaniel J; Jaffro M; Collot S; Ferretti GR; Tiffon C; Mahier-Ait Oukhatar C; Blay JY Ann Oncol; 2020 Feb; 31(2):289-294. PubMed ID: 31959346 [TBL] [Abstract][Full Text] [Related]
27. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Hong DS; Morris VK; El Osta B; Sorokin AV; Janku F; Fu S; Overman MJ; Piha-Paul S; Subbiah V; Kee B; Tsimberidou AM; Fogelman D; Bellido J; Shureiqi I; Huang H; Atkins J; Tarcic G; Sommer N; Lanman R; Meric-Bernstam F; Kopetz S Cancer Discov; 2016 Dec; 6(12):1352-1365. PubMed ID: 27729313 [TBL] [Abstract][Full Text] [Related]
28. Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for Hamid O; Cowey CL; Offner M; Faries M; Carvajal RD Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31653096 [TBL] [Abstract][Full Text] [Related]
29. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965 [TBL] [Abstract][Full Text] [Related]
30. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146 [TBL] [Abstract][Full Text] [Related]
31. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
32. Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial. Wang Z; Qin BD; Ye CY; Wang MM; Yuan LY; Dai WP; Sun L; Liu K; Qin WX; Jiao XD; Li XN; Zang YS Eur J Cancer; 2022 Mar; 163():152-162. PubMed ID: 35074651 [TBL] [Abstract][Full Text] [Related]
33. Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. Kähler KC; Gutzmer R; Meier F; Zimmer L; Heppt M; Gesierich A; Thoms KM; Utikal J; Hassel JC; Loquai C; Pföhler C; Heinzerling L; Kaatz M; Göppner D; Pflugfelder A; Bohne AS; Satzger I; Reinhardt L; Placke JM; Schadendorf D; Ugurel S Front Oncol; 2021; 11():672172. PubMed ID: 34109122 [TBL] [Abstract][Full Text] [Related]
34. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Al-Marrawi MY; Saroya BS; Brennan MC; Yang Z; Dykes TM; El-Deiry WS Cancer Biol Ther; 2013 Aug; 14(8):703-10. PubMed ID: 23792568 [TBL] [Abstract][Full Text] [Related]